Evidence map›Paper›PMID 39327902›Full record

ArticleJournal of proteome research2024

Pilot Study for Deciphering Post-Translational Modifications and Proteoforms of Tau Protein by Capillary Electrophoresis-Mass Spectrometry.

Fei Fang, Tian Xu, Hsiao-Tien Chien Hagar, Stacy Hovde, Min-Hao Kuo, Liangliang Sun

Abstract read
In one paragraph

Article in Journal of proteome research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. The Proteoform Landscape of Tau from the Human Brain.Journal of proteome research · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Fei FangDepartment of Chemistry, Michigan State University, 578 S Shaw Lane, East Lansing, Michigan 48824, United States.
Tian XuDepartment of Chemistry, Michigan State University, 578 S Shaw Lane, East Lansing, Michigan 48824, United States.
Hsiao-Tien Chien HagarDepartment of Biochemistry and Molecular Biology, Michigan State University, 603 Wilson Road, Room 401, East Lansing, Michigan 48824, United States.
Stacy HovdeDepartment of Biochemistry and Molecular Biology, Michigan State University, 603 Wilson Road, Room 401, East Lansing, Michigan 48824, United States.
Min-Hao KuoDepartment of Biochemistry and Molecular Biology, Michigan State University, 603 Wilson Road, Room 401, East Lansing, Michigan 48824, United States.
Liangliang SunDepartment of Chemistry, Michigan State University, 578 S Shaw Lane, East Lansing, Michigan 48824, United States.ORCID 0000-0001-8939-5042

Funding

Treating neurotoxicity and cognitive deficits due to hyperphosphorylated tau.R01NS135693 · NINDS · UNIVERSITY OF VIRGINIA · PI Chia-Yi Kuan, Min-Hao Kuo · 2023 to 2026
$2.4M
Quantitative top-down proteomics of human colorectal cancer cells and tumorsR01CA247863 · NCI · MICHIGAN STATE UNIVERSITY · PI HUMMON, AMANDA B., LIU, XIAOWEN · 2021 to 2025
$1.9M
Advancing top-down proteomics with capillary electrophoresis-mass spectrometryR35GM153479 · NIGMS · MICHIGAN STATE UNIVERSITY · PI Liangliang Sun · 2024 to 2026
$1.4M
Hyperphosphorylated tau and the molecular mechanisms of tauopathyRF1AG077475 · NIA · MICHIGAN STATE UNIVERSITY · PI KUO, MIN-HAO · 2022 to 2022
$1.3M
Hyperphosphorylated tau aggregation-based Alzheimer’s disease early drug discoveryR01AG062435 · NIA · MICHIGAN STATE UNIVERSITY · PI KUO, MIN-HAO · 2019 to 2021
$1.3M
Hyperphosphorylated tau and the molecular mechanisms of tauopathyR01AG077475 · NIA · MICHIGAN STATE UNIVERSITY · PI Min-Hao Kuo · 2025 to 2026
$824k
NCI NIH HHS R01 CA247863NIA NIH HHS R01 AG062435NIA NIH HHS R01 AG077475NIA NIH HHS RF1 AG077475NIGMS NIH HHS R35 GM153479NINDS NIH HHS R01 NS135693
6 · The paper itself

Abstract

Abnormal accumulation of tau protein in the brain is one pathological hallmark of Alzheimer's disease (AD). Many tau protein post-translational modifications (PTMs) are associated with the development of AD, such as phosphorylation, acetylation, and methylation. Therefore, a complete picture of the PTM landscape of tau is critical for understanding the molecular mechanisms of AD progression. Here, we offered a pilot study of combining two complementary analytical techniques, capillary zone electrophoresis (CZE)-tandem mass spectrometry (MS/MS) and reversed-phase liquid chromatography (RPLC)-MS/MS, for bottom-up proteomics of recombinant human tau-0N3R. We identified 50 phosphorylation sites of tau-0N3R in total, which is about 25% higher than that from RPLC-MS/MS alone. CZE-MS/MS provided more PTM sites (i.e., phosphorylation) and modified peptides of tau-0N3R than RPLC-MS/MS, and its predicted electrophoretic mobility helped improve the confidence of the identified modified peptides. We developed a highly efficient capillary isoelectric focusing (cIEF)-MS technique to offer a bird's-eye view of tau-0N3R proteoforms, with 11 putative tau-0N3R proteoforms carrying up to nine phosphorylation sites and lower pI values from more phosphorylated proteoforms detected. Interestingly, under native-like cIEF-MS conditions, we observed three putative tau-0N3R dimers carrying phosphate groups. The findings demonstrate that CE-MS is a valuable analytical technique for the characterization of tau PTMs, proteoforms, and even oligomerization.

Indexed as

Electrophoresis, CapillaryProtein Processing, Post-TranslationalTandem Mass Spectrometrytau ProteinsAcetylationAlzheimer DiseaseChromatography, Reverse-PhaseHumansIsoelectric FocusingPhosphorylationPilot ProjectsProteomicsRecombinant ProteinsRecombinant Proteinstau ProteinsAlzheimer’s diseasecapillary electrophoresis-mass spectrometryphosphorylationpost-translational modificationproteoformtau protein

Identifiers

PMID39327902
PMCPMC11536466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.